Price
No data yet.
Social Signal Score
Analyst Ratings
6 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Reid Waldman
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 51
- Beta
- 1.23
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 294.66
Financials
MANE has only 8 quarterly periods on file — the charts below show the full history available.
Net Income
$-21.00MEBITDA
$-21.00MFree Cash Flow
$-23.29MEPS (diluted)
$-0.50Shares Outstanding (diluted)
42.12M-79.1%Operating Expenses
$28.78MCash & Debt
$798.35MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-70.00M | $-111.91 |
| 2024 | $0.00 | $-26.49M | $-37.05 |
| 2023 | $0.00 | $-16.49M | $-0.08 |
Valuation
MANEhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+66.67%Social Signal Score
Mentions (16)
- Newsseekingalpha.com·12d ago·Neutral
Veradermics, Incorporated (MANE) Discusses Positive Study 302 Part B Results for VDPHL01 in Pattern Hair Loss Transcript Veradermics, Incorporated (MANE) Discusses Positive Study 302 Part B Results for VDPHL01 in Pattern Hair Loss Transcript
View source ↗ - News (RSS)investing·13d ago·Negative
Veradermics to present phase 3 hair loss trial results Monday
View source ↗ - Newsbusinesswire.com·14d ago·Neutral
…lts from Phase 3 ‘302' Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced it will host an investor call and live webcast on Monday, November 9, 2026, at 8:00 am ET to review topline results from Part B of its randomized, double-blind, placebo-controlled …
View source ↗ - News (RSS)fool·28d ago·Neutral
Why This Hair Restoration Biotech's Shares Are Soaring Veradermics' shares are up nearly 270% since its IPO earlier this year.
View source ↗ - News (RSS)seekingalpha·31d ago·Negative
Veradermics, Incorporated (MANE) Discusses Positive Top Line Results From Phase III Study 304 of VDPHL01 in Male Pattern Hair Loss - Slideshow
View source ↗ - Newsseekingalpha.com·34d ago·Neutral
Veradermics, Incorporated (MANE) Discusses Positive Top Line Results From Phase III Study 304 of VDPHL01 in Male Pattern Hair Loss Transcript Veradermics, Incorporated (MANE) Discusses Positive Top Line Results From Phase III Study 304 of VDPHL01 in Male Pattern Hair Loss Transcript
View source ↗ - Newsmarketbeat.com·34d ago·Neutral
Veradermics Phase III Hair Loss Trial Meets All Endpoints, Posts Strong Growth Results Veradermics NYSE: MANE reported positive top-line results from Part A of Study 304, its second Phase III trial of VDPHL01, an extended-release oral minoxidil tablet being developed for men with mild to moderate pattern hair loss.
View source ↗ - News (RSS)investing·35d ago·Negative
Veradermics to present phase 3 hair loss trial results Monday
View source ↗ - Newsbusinesswire.com·35d ago·Negative
…lts from Phase 3 ‘304' Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced it will host an investor call and live webcast on Monday, October 19, 2026, at 8:00 am ET to review results from Part A of its randomized, double-blind, placebo-controlled registra…
View source ↗ - 4chan /biz/biz·41d ago·Negative
>>62773351 gonna go condors on VRTX tomorrow, some others. Anyone here tracking MANE? Nuts volatility on it, I guess it's a hair loss company with a slow release minoxidil?
View source ↗ - News (RSS)seekingalpha·73d ago·Neutral
Veradermics, Incorporated (MANE) Presents at Citigroup's Biopharma Back to School Summit 2026 Prepared Remarks Transcript
View source ↗ - Newsbusinesswire.com·80d ago·Negative
Veradermics to Present at Upcoming September Investor Conferences NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that company management will participate in the following upcoming investor conferences in September: Wells Fargo 21st Annual Healthcare Conference Investor Meetings: Tuesday, September 8, 2026 in Boston, MA Citi…
View source ↗ - News (RSS)investing·90d ago·Neutral
Why is Veradermics stock sliding today?
View source ↗ - News (RSS)investing·90d ago·Neutral
Veradermics stock falls following insider share sale
View source ↗ - News (RSS)seekingalpha·103d ago·Neutral
Veradermics reports Q2 results
View source ↗ - Newsbusinesswire.com·103d ago·Negative
Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today reported financial results for the second quarter ended June 30, 2026, and highlighted recent corporate and clinical progress. “In the second quarter of 2026, we made significa
View source ↗
Earnings
Mon, Mar 29(in 4 months)
Consensus estimate $-0.64 per share
Typical surprise +10.4% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 10$-0.50 vs $-0.56beat
- Tue, Aug 11$-0.58 vs $-0.65beat
- Tue, May 12$-1.32 vs $-0.56miss
- Wed, Feb 25$-1.63 vs $-1.81beat
Estimates and results for MANE via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MANE officers and directors.
- Bought
- —
- Sold
- $253.5m
0 trades
19 trades
- Enright Patrick Gsold
- Enright Patrick Gsold
- Longitude Capital Partners V, Llcsold
- Longitude Capital Partners V, Llcsold
- Montanova Capital, Llcsold
- Montanova Capital, Llcsold
- Durso Timothy Augustsold
- Durso Timothy Augustsold
11 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in MANE.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
